regeneron dupilumab - Search News

GlobalData on MSN · 3d

FDA to review Sanofi and Regeneron’s Dupixent sBLA for bullous pemphigoid

As Sanofi and Regeneron await the FDA decision, a legal dispute between the partners over commercialisation details continues.

Dupilumab Under FDA Priority Review for Bullous Pemphigoid

Patients treated with on dupilumab showed significant improvement in sustained BP remission compared with those on placebo.

Business Insider · 4d

Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for the Targeted Treatment of Bullous Pemphigoid (BP)

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025Priority

Monthly Prescribing Reference · 3d

Dupilumab Gets Priority Review for Bullous Pemphigoid

Dupilumab, an interleukin-4 receptor antagonist, is expected to decrease the type 2 inflammation seen in bullous pemphigoid.

Sanofi and Regeneron’s Dupixent granted FDA priority review for bullous pemphigoid

Sanofi and Regeneron’s Dupixent (dupilumab) has been accepted for priority review by the US Food and Drug Administration (FDA) to treat adults with bullous pemphigoid (BP).

Business Insider · 4d

Press Release: Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid

Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoidIf approved, Dupixent would be the first and only

Regeneron and Sanofi Announce FDA Priority Review for Dupixent® as Potential First Targeted Treatment for Bullous Pemphigoid

Regeneron Pharmaceuticals, Inc. and Sanofi announced that the FDA has accepted a supplemental Biologics License Application for Dupixent (dupilumab) to treat adults with bullous pemphigoid (BP), a ...

Can Dupixent plug treatment gap in bullous pemphigoid?

Bullous pemphigoid (BP), which has no FDA-approved targeted therapies, leads to reddening of the skin and the formation of ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results